[November 28, 2017] |
|
Cambridge BioMarketing Demonstrates Strong Momentum in 2017
Cambridge
BioMarketing, an Ashfield company, part of UDG Healthcare plc and
the world's leading rare disease agency, today announced it has added 20
new employees and bolstered its staff expertise in the agency's rare
oncology practice. The staff expansion and expanded focus on the rare
oncology therapeutic area comes as the Federal Drug Administration (FDA)
has approved 34 orphan drugs thus far in 2017, illustrating the
continued growth of the rare disease market. Further, the agency has
received multiple accolades from industry and local organizations for
its creative campaigns aimed at elevating treatments and movements
related to rare diseases.
New hires have joined Cambridge BioMarketing in both its Boston- and
Oakland, Calif.-based locations to continue building awareness for rare
disease. As part of the hiring investment, the agency welcomes Michael
Tonzola as Group Management Supervisor. An expert in rare oncology,
Tonzola brings more than 15 years of industry experience to the agency
and will lead the rare cancer practice, expanding Cambridge
BioMarketing's expertise in this ultra-niche therapeutic area.
"Moving into 2018, we are excited to build off this momentum and double
down on our dedication to elevate the voices of rare disease patients
and advocates, while making a difference in as many lives as possible,"
said Maureen Franco, CEO of Cambridge BioMarketing.
As the rare disease landscape has evolved, Cambridge BioMarketing
continues to lead by designing innovative, creative campaigns that
promote patient advocacy and build awareness. As a result, the agency
has been recognized with several industry awards for its steadfast work
and dedication to the rare cause. In 2017 specifically, Cambridge
BioMarketing has received more than 10 accolades from pharmaceutical,
marketing, and Boston-based organizations for its creative work and
strategic leadership:
-
MarCom Awards: Cambridge BioMarketing received five accolades
from MarCom Awards, which honors excellence in marketing:
-
Platinum Award for Strategic Communications | Marketing /
Promotions for Product Launch based on the company's work with
Intercept Pharmaceuticals for Ocaliva.com: Welcome to Your World
of PBC Treatment for Intercept Pharmaceuticals
-
Platinum Award in the Digital Media | Web Video for
Self-Promotion, honoring the company's 2016 holiday campaign
Give Pause for Some Good: The Mannequin Challenge
-
Gold Award in Strategic Communications | Public Relations for
Traditional and Social Media Campaign related to the agency's
work around Rare Disease Day 2017 with its #SupportTheSearch
project
-
Honorable Mention for Digital Media | Medical Website to
commemorate Cambridge BioMarketing and Horizon Pharma's
collaboration on UCDInsights.com
-
Honorable Mention in Video / Audio to recognize the Virtual
Reality UCD Tightrope Challenge created by Cambridge BioMarketing
and Horizon Pharma
-
Medical Marketing & Media (MM&M) Annual Awards:
the company's client campaign with Intercept Pharmaceuticals around
Ocaliva.com was also recognized as a Silver
Winner in the Orphan Product Marketing Initiative category
-
WEGO Health: The agency was named a Finalist in the Healthcare
Collaborator Section
-
The Boston Globe: Franco was named to the 'Top 100
Women-Led Businesses' list for the fifth consecutive year
Added Franco: "As pharma and biotech companies continue to invest in
pursuing drugs and treatments for rare disease, we are drawing from our
deep knowledge of the industry while bringing on fresh insights to tell
the stories of patients, their advocacy networks, and the companies that
are coming to their aid."
The rare disease market has witnessed accelerated growth in recent
years. In 2016 alone, the FDA received a record-breaking 582 requests
for orphan drug designations. Industry experts attribute the focus to a
combination of gene editing and new technologies that can reduce common
barriers for these patients, such as lack of treatments and long lead
times for accurate diagnoses.
Looking ahead, Market
Research Future's Global Orphan Diseases Market Report forecasts the
rare disease industry will reach $579.6B by 2022, citing North America
as the largest of the orphan disease markets. While the majority of
Cambridge BioMarketing's clients reside in the U.S., the agency plans to
translate best practices to its international clientele, expanding its
global footprint under Ashfield, part of UDG Healthcare plc. Cambridge
BioMarketing also anticipates additional traction in raising rare
disease awareness in early 2018 through its work associated with International
Rare Disease Day (RDD), held each year on Feb. 28. In the past,
Cambridge BioMarketing has participated in RDD with the launch of Rare
in Common (2015) and #SupportTheSearch
campaign (2016).
About Cambridge BioMarketing Founded in 2001, Cambridge
BioMarketing is a U.S.-based communications agency specializing in rare
orphan diseases with over 100 employees. Headquartered in Cambridge,
Mass. with offices in Oakland, Calif., Cambridge BioMarketing is an
industry leader in orphan drug launches, advising pharmaceutical
companies with an integrated focus on both traditional healthcare
professional (HCP) programs and direct-to-patient work. In partnering
with predominantly pharmaceutical and biotech customers, the agency's
goal is to bring physicians, specialists, and patient communities
together on behalf of clients to transform human health in the face of
devastating, under-appreciated disease states. Cambridge BioMarketing's
primary service offerings include: launch readiness support; digital
strategy; market analytics; integrated marketing; patient identification
and acquisition; medical affairs support; line extensions and patient
retention and adherence programs.
For more information, please go to: http://cambridgebmg.com/
About Ashfield Ashfield Commercial & Medical Services, part
of UDG Healthcare plc, is a global leader in providing outsourced
healthcare services to pharmaceutical, device and biotech companies. The
company has 6,000 employees, operating in 23 countries and delivering
services in over 50 countries across Europe, North America, South
America and Asia and works with more than 250 companies, including all
the world's top 25 pharmaceutical companies. Its mission is to partner
with its clients, improving lives by helping healthcare professionals
and patients get the medicines, knowledge and support they need.
Ashfield's provides contract sales teams, customer service reps, medical
science liaison officers, remote detailing, nurse educators, medical
information, healthcare communications, market access, market research,
training, event management, digital, creative and pharmacovigilance
services.
For more information, go to https://www.ashfieldhealthcare.com/en/
View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005033/en/
[ Back To TMCnet.com's Homepage ]
|